Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is well-positioned for growth in the cell and gene therapy industry, driven by their innovative biopreservation products and increasing use in clinical trials. The company's strong financial performance, including a 21% year-over-year increase in revenue and 30% increase in adjusted EBITDA, bodes well for the future of the company. The pending acquisition by Repligen is expected to bring additional synergies and accretion to the company, further enhancing its growth potential and solidifying its position in the market.

Bears say

BioLife Solutions is set to be acquired by Repligen, which management states was a logical outcome following years of portfolio simplification and refocusing around the company's core biopreservation media franchise. While the company's position in biopreservation and exposure to cell and gene therapy growth is positive, the acquisition has largely captured the near-term value creation opportunity, leading to a new Hold rating and price target of $31.

BioLife Solutions (BLFS) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Hold based on their latest research and market trends.

According to 5 analysts, BioLife Solutions (BLFS) has a Hold consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.